Announcements Trials
Browse Landscape

Phase

Phase 1/2 7Phase 2 6Phase 1 5Phase 3 2Phase NA 1Phase 2/3 1

Status

Completed 3Terminated 2

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Multiple Myeloma 50Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Recurrence 9Burkitt Lymphoma 7Neoplasms, Plasma Cell 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma 5Immunoglobulin Light-chain Amyloidosis 5Hodgkin Disease 4Lymphoma, T-Cell 3Lymphoma, Non-Hodgkin 3Lymphoma, B-Cell 3Leukemia 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Oligodendroglioma 2Neoplasms 2Neoplasm Metastasis 2Mesothelioma 2Lymphoma, T-Cell, Cutaneous 2Leukemia, Myeloid, Acute 2Leukemia, Hairy Cell 2Leukemia, Biphenotypic, Acute 2Hematologic Neoplasms 2Glioblastoma 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Astrocytoma 2Amyloidosis 2Waldenstrom Macroglobulinemia 1Vascular Diseases 1Uveal Melanoma 1

Interventions

Cyclophosphamide 17Dexamethasone 15Bortezomib 14fludarabine phosphate 12Melphalan 12Lenalidomide 10fludarabine 9Filgrastim 8pomalidomide 7Tacrolimus 7Peripheral Blood Stem Cell Transplantation 7Rituximab 6Radiotherapy 6Etoposide 6Whole-Body Irradiation 5Cord Blood Stem Cell Transplantation 5Calcium Dobesilate 5Busulfan 5Antilymphocyte Serum 5sargramostim 4Sirolimus 4Panobinostat 4Mycophenolic Acid 4Methylprednisolone 4Cyclosporine 4carfilzomib 3Vorinostat 3Stem Cell Transplantation 3Prednisone 3Methotrexate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms, Plasma Cell × Calcium Dobesilate × Clear all
NCT03702725 2026-01-06

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Alliance Foundation Trials, LLC.

Phase 1 Completed
14 enrolled 15 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01440582 2019-03-04

Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

M.D. Anderson Cancer Center

Phase 1 Completed
77 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01985477 2016-09-14

Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma

M.D. Anderson Cancer Center

Phase 1 Terminated
2 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01807286 2016-05-13

Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis

M.D. Anderson Cancer Center

Phase 1 Terminated
3 enrolled
Plasma cell

Amyloidosis, Neoplasms, Plasma Cell

NCT00258245 2013-04-29

Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Barbara Ann Karmanos Cancer Institute

Phase 1 Completed
5 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡